R P Mason

Summary

Affiliation: Brigham and Women's Hospital
Country: USA

Publications

  1. ncbi X-ray diffraction analysis of membrane structure changes with oxidative stress
    R Preston Mason
    Cardiovascular Division, Department of Medicine, Harvard Medical School, Boston, MA, USA
    Methods Mol Biol 196:69-78. 2002
  2. ncbi Cholesterol crystallization and macrophage apoptosis: implication for atherosclerotic plaque instability and rupture
    Yong Jian Geng
    Center for Cardiovascular Biology and Atherosclerosis, University of Texas Health Science Center at Houston School of Medicine, 6431 Fannin Street, MSB 6 001, Houston, TX 77030, USA
    Biochem Pharmacol 66:1485-92. 2003
  3. ncbi Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism
    R Preston Mason
    Elucida Research, Beverly, Massachusetts 01915 0091, USA
    J Biol Chem 281:9337-45. 2006
  4. ncbi A rationale for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidence
    R Preston Mason
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Curr Drug Targets Cardiovasc Haematol Disord 5:489-501. 2005
  5. ncbi Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity
    R Preston Mason
    Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Cardiovasc Pharmacol 48:862-9. 2006
  6. ncbi Pleiotropic effects of calcium channel blockers
    R Preston Mason
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, PO Box 7100, 100 Cummings Center, Suite 135L, Beverly, MA, 01915, USA
    Curr Hypertens Rep 14:293-303. 2012
  7. ncbi Nitric oxide mechanisms in the pathogenesis of global risk
    R Preston Mason
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    J Clin Hypertens (Greenwich) 8:31-8; quiz 40. 2006
  8. ncbi Evolving mechanisms of action of beta blockers: focus on nebivolol
    R Preston Mason
    Cardiovascular Division, Department of Medicine Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    J Cardiovasc Pharmacol 54:123-8. 2009
  9. ncbi Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions
    R Preston Mason
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 96:11F-23F. 2005
  10. ncbi Atheroprotective effects of long-acting dihydropyridine-type calcium channel blockers: evidence from clinical trials and basic scientific research
    R Preston Mason
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Cerebrovasc Dis 16:11-7. 2003

Collaborators

Detail Information

Publications46

  1. ncbi X-ray diffraction analysis of membrane structure changes with oxidative stress
    R Preston Mason
    Cardiovascular Division, Department of Medicine, Harvard Medical School, Boston, MA, USA
    Methods Mol Biol 196:69-78. 2002
  2. ncbi Cholesterol crystallization and macrophage apoptosis: implication for atherosclerotic plaque instability and rupture
    Yong Jian Geng
    Center for Cardiovascular Biology and Atherosclerosis, University of Texas Health Science Center at Houston School of Medicine, 6431 Fannin Street, MSB 6 001, Houston, TX 77030, USA
    Biochem Pharmacol 66:1485-92. 2003
    ..These results suggest that hyperthermia inhibits cholesterol crystallization and promotes apoptotic effects of oxysterols on macrophages...
  3. ncbi Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism
    R Preston Mason
    Elucida Research, Beverly, Massachusetts 01915 0091, USA
    J Biol Chem 281:9337-45. 2006
    ..These findings indicate an atheroprotective effect of ATM on membrane lipid organization through a potent antioxidant mechanism...
  4. ncbi A rationale for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidence
    R Preston Mason
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Curr Drug Targets Cardiovasc Haematol Disord 5:489-501. 2005
    ....
  5. ncbi Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity
    R Preston Mason
    Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Cardiovasc Pharmacol 48:862-9. 2006
    ..These results demonstrate that nebivolol inhibits endothelial dysfunction through a potent antioxidant mechanism attributed to its physicochemical interactions with the membrane, independent of beta1-blockade activity...
  6. ncbi Pleiotropic effects of calcium channel blockers
    R Preston Mason
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, PO Box 7100, 100 Cummings Center, Suite 135L, Beverly, MA, 01915, USA
    Curr Hypertens Rep 14:293-303. 2012
    ..Furthermore, by elucidating the biological mechanisms by which cardiovascular risk factors lead to vascular injury, we may highlight common pathways and identify novel therapeutic targets...
  7. ncbi Nitric oxide mechanisms in the pathogenesis of global risk
    R Preston Mason
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    J Clin Hypertens (Greenwich) 8:31-8; quiz 40. 2006
    ..This effect may help explain the cardioprotective benefits of these agents and may stimulate further use of nitric oxide modulation for the treatment of cardiovascular risk factors and manifestations of cardiovascular disease...
  8. ncbi Evolving mechanisms of action of beta blockers: focus on nebivolol
    R Preston Mason
    Cardiovascular Division, Department of Medicine Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    J Cardiovasc Pharmacol 54:123-8. 2009
    ..As a result, its hemodynamic profile is clearly different from those of traditional beta-blockers. This review will evaluate this class of agents and the basis for their differences in clinical use...
  9. ncbi Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions
    R Preston Mason
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 96:11F-23F. 2005
    ..To understand the biochemical basis for such differences among statins, this article reviews their physicochemical properties and pharmacology at the molecular level...
  10. ncbi Atheroprotective effects of long-acting dihydropyridine-type calcium channel blockers: evidence from clinical trials and basic scientific research
    R Preston Mason
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Cerebrovasc Dis 16:11-7. 2003
    ..These findings support a broader therapeutic role for third-generation dihydropyridine-type CCBs in the treatment of atherosclerosis...
  11. ncbi Membrane microdomains and vascular biology: emerging role in atherogenesis
    R Preston Mason
    Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, USA
    Circulation 107:2270-3. 2003
  12. ncbi Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence
    R Preston Mason
    Membrane Biophysics Laboratory, Division of Cardiology, Department of Medicine and Biochemistry, MCP Hahnemann University School of Medicine, Allegheny Campus, Pittsburgh, PA, USA
    Atherosclerosis 165:191-9. 2002
    ....
  13. ncbi Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil
    R Preston Mason
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Vasc Health Risk Manag 7:405-16. 2011
    ....
  14. ncbi Mechanisms of atherosclerotic plaque stabilization for a lipophilic calcium antagonist amlodipine
    R P Mason
    Membrane Biophysics Laboratory, Division of Cardiology, Department of Medicine and Biochemistry, Medical College of Pennsylvania Hahnemann University School of Medicine, Pittsburgh, Pennsylvania, USA
    Am J Cardiol 88:2M-6M. 2001
    ..In this article, cellular and molecular mechanisms of action that may contribute to a beneficial role for a calcium antagonist in the treatment of atherosclerosis will be reviewed...
  15. ncbi A rationale for combination therapy in risk factor management: a mechanistic perspective
    R Preston Mason
    Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Am J Med 118:54-61. 2005
    ..The clinical implications of these observations are discussed in this article in the context of cardiovascular risk factor management strategies...
  16. ncbi Targeting nitric oxide with drug therapy
    R Preston Mason
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    J Clin Hypertens (Greenwich) 8:40-52. 2006
    ..The NO-promoting actions of these established drugs provide some insight into their known benefits and suggest possible therapeutic potential...
  17. ncbi Rofecoxib increases susceptibility of human LDL and membrane lipids to oxidative damage: a mechanism of cardiotoxicity
    R Preston Mason
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    J Cardiovasc Pharmacol 47:S7-14. 2006
    ..These findings provide a mechanistic rationale for differences in cardiovascular risk among COX-selective inhibitors because of their intrinsic physicochemical properties...
  18. ncbi Molecular basis of differences among statins and a comparison with antioxidant vitamins
    R Preston Mason
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 98:34P-41P. 2006
    ..In addition, the possibility that statin benefits on stroke reflect pleiotropic effects is reviewed. Finally, possible reasons for differences between the effects of atorvastatin metabolites and antioxidant vitamins are considered...
  19. ncbi Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress
    R Preston Mason
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Circulation 109:II34-41. 2004
    ..The relationships between membrane microdomains, cholesterol biosynthesis, and endothelial function will be discussed...
  20. ncbi Antioxidant and cytoprotective activities of the calcium channel blocker mibefradil
    R P Mason
    Department of Biochemistry, MCP Hahnemann School of Medicine, Allegheny University of the Health Sciences, Pittsburgh, PA 15212 4772, USA
    Biochem Pharmacol 55:1843-52. 1998
    ..These findings indicate that the chemical structure of mibefradil contributes to biophysical interactions with the cell membrane that underlie antioxidant and cytoprotective activities in models of oxidative stress...
  21. ncbi Neuroprotective activities of carvedilol and a hydroxylated derivative: role of membrane biophysical interactions
    P G Lysko
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA, USA
    Biochem Pharmacol 56:1645-56. 1998
    ....
  22. ncbi [Membrane biophysical interaction of amlodipine and antioxidant properties]
    R P Mason
    Département de Médecine et de Biochimie, MCP Hahnemann University School of Medicine, Pittsburg, Pennsylvania, USA
    Drugs 59:9-16. 2000
    ....
  23. ncbi Antioxidant activity of the monoamine oxidase B inhibitor lazabemide
    R P Mason
    Membrane Biophysics Laboratory, Departments of Biochemistry and Medicine, MCP Hahnemann University School of Medicine, Allegheny Campus, Pittsburgh, PA, USA
    Biochem Pharmacol 60:709-16. 2000
    ..These findings indicate that lazabemide is a potent and concentration-dependent inhibitor of membrane oxy-radical damage as a result of inhibiting membrane lipid peroxidation, independent of MAO-B interactions...
  24. ncbi Mechanisms of plaque stabilization for a charged calcium channel blocker in coronary artery disease
    R P Mason
    Department of Medicine, MCP Hahnemann University School of Medicine, Pittsburgh, Pennsylvania, USA
    Pharmacotherapy 21:209S-215S. 2001
    ..These results have renewed interest in potential plaque stabilization properties of third-generation calcium channel blockers and their possible therapeutic role in CAD...
  25. ncbi Evidence for distinct cholesterol domains in fiber cell membranes from cataractous human lenses
    R F Jacob
    Membrane Biophysics Laboratory, Department of Medicine, MCP Hahnemann University School of Medicine, Allegheny Campus, Pittsburgh, Pennsylvania 15212 4772, USA
    J Biol Chem 276:13573-8. 2001
    ....
  26. ncbi 7-Ketocholesterol forms crystalline domains in model membranes and murine aortic smooth muscle cells
    J E Phillips
    Membrane Biophysics Laboratory, Department of Medicine, Division of Cardiology, MCP Hahnemann University, Allegheny Campus, 320 East North Avenue, Pittsburgh, PA 15212-4772, USA
    Atherosclerosis 159:125-35. 2001
    ..While these domains may decrease its cytotoxicity by inducing the formation of sterol crystals in smooth muscle cells, they may, in a broader capacity, contribute to the sterol crystals found in advanced atherosclerotic lesions...
  27. ncbi Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine
    R P Mason
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass, USA
    Arterioscler Thromb Vasc Biol 23:2155-63. 2003
    ....
  28. ncbi Alzheimer's disease amyloid beta peptide 25-35 inhibits lipid peroxidation as a result of its membrane interactions
    M F Walter
    Laboratory for Membrane Structure Studies, MCP Hahnemann School of Medicine, Allegheny University of the Health Sciences, Pittsburgh, Pennsylvania 15212 4772, USA
    Biochem Biophys Res Commun 233:760-4. 1997
    ..These findings indicate that the amphiphilic A beta(25-35) peptide inhibits lipid peroxidation at low concentrations as a result of physicochemical interactions with the membrane lipid bilayer...
  29. ncbi Calcium channel blockers, apoptosis and cancer: is there a biologic relationship?
    R P Mason
    Cardiovascular and Pulmonary Research Institute, Department of Biochemistry, MCP Hahnemann University School of Medicine, Pittsburgh, Pennsylvania, USA
    J Am Coll Cardiol 34:1857-66. 1999
    ..A comprehensive analysis of the basic and clinical evidence does not support a causal relationship between the therapeutic use of CCBs and an increased incidence of cancer development as a result of interfering with apoptosis...
  30. ncbi The editor's roundtable: revisiting the role of beta blockers in hypertension
    William C Roberts
    Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas, USA
    Am J Cardiol 100:253-67. 2007
  31. ncbi A biological rationale for the cardiotoxic effects of rofecoxib: comparative analysis with other COX-2 selective agents and NSAids
    R Preston Mason
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Subcell Biochem 42:175-90. 2007
    ..These findings provide a compelling rationale for distinguishing the differences in cardiovascular risk among COX-selective inhibitors on the basis of their intrinsic physico-chemical properties...
  32. ncbi Synergistic effect of amlodipine and atorvastatin in reversing LDL-induced endothelial dysfunction
    R Preston Mason
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Pharm Res 25:1798-806. 2008
    ..Statins and certain calcium channel blockers may improve nitric oxide (NO) release and endothelial function through various mechanisms, but their combined effects are not well understood...
  33. ncbi Effect of beta-blockers on endothelial function during biological aging: a nanotechnological approach
    Philip Funovic
    Department of Orthopaedics, Medical University of Vienna, Vienna, Austria
    J Cardiovasc Pharmacol 51:208-15. 2008
    ..This effect was not observed with atenolol, but L-arginine, sepiapterin, and superoxide dismutase were beneficial...
  34. ncbi Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor: a new approach to risk factor management
    R Preston Mason
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Drugs 68:885-900. 2008
    ..This article provides an overview of the evidence for this new approach and recommends applications for use in clinical settings...
  35. ncbi Biologic activity of carotenoids related to distinct membrane physicochemical interactions
    Hyesun McNulty
    Elucida Research, Beverly, MA 01915, USA
    Am J Cardiol 101:20D-29D. 2008
    ..This relation of structure and function may explain the differences in biologic activity reported for various carotenoids, with important therapeutic implications...
  36. ncbi Differential effects of carotenoids on lipid peroxidation due to membrane interactions: X-ray diffraction analysis
    Hyesun P McNulty
    Elucida Research, 100 Cummings Center, Suite 135L, P O Box 7100, Beverly, MA 01915 0091, USA
    Biochim Biophys Acta 1768:167-74. 2007
    ..These findings indicate distinct effects of carotenoids on lipid peroxidation due to membrane structure changes. These contrasting effects of carotenoids on lipid peroxidation may explain differences in their biological activity...
  37. ncbi Influence of serum cholesterol on atherogenesis and intimal hyperplasia after angioplasty: inhibition by amlodipine
    Mark B Kahn
    Department of Surgery, Thomas Jefferson University College of Medicine, Philadelphia, Pennsylvania 19107, USA
    Am J Physiol Heart Circ Physiol 288:H591-600. 2005
    ..This study establishes a causal role between serum HC and the development of spontaneous and angioplasty-induced lesions and the ability of amlodipine to disrupt this action by a novel remodelling action on the SMC membrane...
  38. ncbi Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs
    Mary F Walter
    Elucida Research LLC, 100 Cummings Center, Suite 135L, Beverly, MA 01915, USA
    Atherosclerosis 177:235-43. 2004
    ..These findings may provide mechanistic insight into reported differences in cardiovascular risk for COX-2 inhibitors...
  39. ncbi Lipid peroxidation induces cholesterol domain formation in model membranes
    Robert F Jacob
    Elucida Research, Beverly, Massachusetts 01915 0091, USA
    J Biol Chem 280:39380-7. 2005
    ....
  40. ncbi Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans
    R Preston Mason
    Elucida Research, Beverly, Massachusetts, USA
    Circulation 112:3795-801. 2005
    ..Nebivolol decreased O2- and ONOO- concentrations and restored NO bioavailability in blacks to the level recorded in cells from whites, independently of beta1-selective blockade...
  41. ncbi The antioxidant effects of statins
    Jean Davignon
    Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, and University of Montreal Hospital Medical Centre, Montreal, QC, Canada
    Coron Artery Dis 15:251-8. 2004
    ..The antioxidant properties of statins extend to organ protection especially the myocardium and the lungs...
  42. ncbi Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease: a longitudinal analysis of the PREVENT study
    Mary F Walter
    Elucida Research, Beverly, Massachusetts, USA
    J Am Coll Cardiol 44:1996-2002. 2004
    ..0001). CONCLUSIONS: Serum levels of TBARS were strongly predictive of cardiovascular events in patients with stable CAD, independently of traditional risk factors and inflammatory markers...
  43. ncbi Circulating lipid hydroperoxides predict cardiovascular events in patients with stable coronary artery disease: the PREVENT study
    Mary F Walter
    Elucida Research, Beverly, Massachusetts, USA
    J Am Coll Cardiol 51:1196-202. 2008
    ..This study was designed to determine the predictive value of lipid hydroperoxide (LOOH) levels for adverse cardiovascular outcomes in patients with stable coronary artery disease (CAD)...
  44. ncbi A membrane defect in the pathogenesis of the Smith-Lemli-Opitz syndrome
    Thomas N Tulenko
    Departments of Surgery and Biochemistry and Molecular Pharmacology, Thomas Jefferson University College of Medicine, Philadelphia, PA, USA
    J Lipid Res 47:134-43. 2006
    ..These data indicate that the disturbance in membrane sterol content in SLOS, likely at the level of membrane caveolae, directly contributes to the widespread tissue abnormalities in this disease...
  45. ncbi Direct perturbation of lens membrane structure may contribute to cataracts caused by U18666A, an oxidosqualene cyclase inhibitor
    Richard J Cenedella
    Department of Biochemistry, Kirksville College of Osteopathic Medicine, Kirksville, MO 63501, USA
    J Lipid Res 45:1232-41. 2004
    ..Induction of apoptosis may begin by intercalation of U18666A into cell membranes. By increasing membrane structural order, U18666A may also increase light scatter, thus directly contributing to lens opacification...
  46. ncbi Regulation of the gating of BKCa channel by lipid bilayer thickness
    Chunbo Yuan
    Brudnick Neuropsychiatric Research Institute, University of Massachusetts Medical School, Worcester, Massachusetts 01604, USA
    J Biol Chem 282:7276-86. 2007
    ..We suggest a simple mechanical model that combines forces of lateral stress within the lipid bilayer with local hydrophobic mismatch between lipids and the protein to account for the biphasic modulation of BK(Ca) gating...